These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11435890)

  • 1. T cells activated in vitro as immunotherapy for renal cell carcinoma: characterization of 2 effector T-cell populations.
    Garlie NK; Siebenlist RE; Lefever AV
    J Urol; 2001 Jul; 166(1):299-303. PubMed ID: 11435890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.
    Gigante M; Mandic M; Wesa AK; Cavalcanti E; Dambrosio M; Mancini V; Battaglia M; Gesualdo L; Storkus WJ; Ranieri E
    J Immunother; 2008 Apr; 31(3):254-62. PubMed ID: 18317362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J; Hu P; Khawli LA; Epstein AL
    Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma.
    Sievers E; Albers P; Schmidt-Wolf IG; Märten A
    J Urol; 2004 Jan; 171(1):114-9. PubMed ID: 14665857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells.
    Harlin H; Artz AS; Mahowald M; Rini BI; Zimmerman T; Vogelzang NJ; Gajewski TF
    Bone Marrow Transplant; 2004 Mar; 33(5):491-7. PubMed ID: 14716341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy.
    Verra N; de Jong D; Bex A; Batchelor D; Dellemijn T; Sein J; Nooijen W; Meinhardt W; Horenblas S; de Gast G; Vyth-Dreese F
    Eur Urol; 2005 Sep; 48(3):527-33. PubMed ID: 16115526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells partially abrogate the regulatory activity of CD4+CD25+ T cells present in the human peripheral blood.
    Ahn JS; Krishnadas DK; Agrawal B
    Int Immunol; 2007 Mar; 19(3):227-37. PubMed ID: 17289657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas.
    Attig S; Hennenlotter J; Pawelec G; Klein G; Koch SD; Pircher H; Feyerabend S; Wernet D; Stenzl A; Rammensee HG; Gouttefangeas C
    Cancer Res; 2009 Nov; 69(21):8412-9. PubMed ID: 19843860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer.
    Lamers CH; Willemsen RA; Luider BA; Debets R; Bolhuis RL
    Cancer Gene Ther; 2002 Jul; 9(7):613-23. PubMed ID: 12082462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Zeta chain level of T and NK cells in patients with renal-cell carcinoma and bladder cancer and its clinical significance].
    Han Y; Li CL; Lu L; Zhou CX; Ma WB; Wang DM; Zhang SR
    Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):158-60. PubMed ID: 15196436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma.
    Viey E; Laplace C; Escudier B
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):973-86. PubMed ID: 16336088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of interleukin-15 on effector and regulatory function of anti-CD3/anti-CD28-stimulated CD4(+) T cells.
    Lin SJ; Cheng PJ; Hsiao SS
    Bone Marrow Transplant; 2006 May; 37(9):881-7. PubMed ID: 16565741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.
    Ichihara F; Kono K; Takahashi A; Kawaida H; Sugai H; Fujii H
    Clin Cancer Res; 2003 Oct; 9(12):4404-8. PubMed ID: 14555512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expansion of natural killer cell receptor (CD94/NKG2A)-expressing cytolytic CD8 T cells and CD4+CD25+ regulatory T cells from the same cord blood unit.
    Tanaka J; Sugita J; Kato N; Toubai T; Ibata M; Shono Y; Ota S; Kondo T; Kobayashi T; Kobayashi M; Asaka M; Imamura M
    Exp Hematol; 2007 Oct; 35(10):1562-6. PubMed ID: 17681668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
    Thompson JA; Figlin RA; Sifri-Steele C; Berenson RJ; Frohlich MW
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3562-70. PubMed ID: 14506142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.
    Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K
    Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.